58 results on '"Mufti, G"'
Search Results
2. ‘Off-the-shelf’ allogeneic CAR T cells: development and challenges
3. Late treatment-related mortality versus competing causes of death after allogeneic transplantation for myelodysplastic syndromes and secondary acute myeloid leukemia
4. Validation of the revised IPSS at transplant in patients with myelodysplastic syndrome/transformed acute myelogenous leukemia receiving allogeneic stem cell transplantation: a retrospective analysis of the EBMT chronic malignancies working party
5. Erratum: Allogeneic haematopoietic stem cell transplant in patients with lower risk myelodysplastic syndrome: a retrospective analysis on behalf of the Chronic Malignancy Working Party of the EBMT
6. Preclinical modeling of myelodysplastic syndromes
7. Allogeneic haematopoietic stem cell transplant in patients with lower risk myelodysplastic syndrome: a retrospective analysis on behalf of the Chronic Malignancy Working Party of the EBMT
8. Clinical significance of acquired somatic mutations in aplastic anaemia
9. Impact of TP53 mutation variant allele frequency on phenotype and outcomes in myelodysplastic syndromes
10. High concordance of genomic and cytogenetic aberrations between peripheral blood and bone marrow in myelodysplastic syndrome (MDS)
11. The relationship of TP53 R72P polymorphism to disease outcome and TP53 mutation in myelodysplastic syndromes
12. A multicentre UK study of GVHD following DLI: Rates of GVHD are high but mortality from GVHD is infrequent
13. Relationship of different platelet response criteria and patient outcomes in a romiplostim myelodysplastic syndromes trial
14. Allogeneic stem cell transplantation using alemtuzumab-containing regimens in severe aplastic anemia
15. The impact of center experience on results of reduced intensity: allogeneic hematopoietic SCT for AML. An analysis from the Acute Leukemia Working Party of the EBMT
16. Standardization of flow cytometry in myelodysplastic syndromes: a report from an international consortium and the European LeukemiaNet Working Group
17. Long-term transfusion independence in del(5q) MDS patients who discontinue lenalidomide
18. Efficacy of bimonthly extracorporeal photopheresis in refractory chronic mucocutaneous GVHD
19. Reducing MCM levels in human primary T cells during the G0→G1 transition causes genomic instability during the first cell cycle
20. Allogeneic haematopoietic SCT for chronic myelomonocytic leukaemia: a single-centre experience
21. Impact of pretransplant comorbidities on alemtuzumab-based reduced-intensity conditioning allogeneic hematopoietic SCT for patients with high-risk myelodysplastic syndrome and AML
22. Mucous membrane pemphigoid following reduced intensity conditioning allogeneic haematopoietic SCT for biphenotypic leukaemia
23. Outcome of second allogeneic transplants using reduced-intensity conditioning following relapse of haematological malignancy after an initial allogeneic transplant
24. Mixed donor chimaerism in recipient fingernails following reduced-intensity conditioning haematopoietic SCT
25. Sustained neurological improvement following reduced-intensity conditioning allogeneic haematopoietic stem cell transplantation for late-onset Krabbe disease
26. Chimerism does not predict for outcome after alemtuzumab-based conditioning: lineage-specific analysis of chimerism of specific diseases may be more informative
27. Tumor-derived IL-6 may contribute to the immunological defect in CLL
28. Clonal gammopathies following alemtuzumab-based reduced intensity conditioning haematopoietic stem cell transplantation: association with chronic graft-versus-host disease and improved overall survival
29. CDKN2B methylation status and isolated chromosome 7 abnormalities predict responses to treatment with 5-azacytidine
30. Low IPSS score and bone marrow hypocellularity in MDS patients predict hematological responses to antithymocyte globulin
31. Sarcoidosis as an unusual cause of hepatic dysfunction following reduced intensity conditioned allogeneic stem cell transplantation
32. Incidence and management of hepatic venoocclusive disease in 237 patients undergoing reduced-intensity conditioning (RIC) haematopoietic stem cell transplantation (HSCT)
33. Prolonged remission in a case of Richter's transformation of B-cell chronic lymphocytic leukaemia following adoptive immunotherapy
34. The JAK2 V617F mutation is rare in RARS but common in RARS-T
35. Ten years outcome analysis of corporeal plication for Peyronie’s Disease
36. Disseminated herpes virus (HSV-2) infection with rhabdomyolysis and hemophagocytic lymphohistiocytosis in a patient with bone marrow failure syndrome
37. Presence of JAK2 V617F tyrosine kinase mutation as a myeloid-lineage-specific mutation in chronic neutrophilic leukaemia
38. Topical issues in unrelated donor haematopoietic stem cell transplants: a report from a workshop convened by the Anthony Nolan Trust in London – 2005
39. A novel MHC-associated Proteinase 3 peptide isolated from primary chronic myeloid leukaemia cells further supports the significance of this antigen for the immunotherapy of myeloid leukaemias
40. The JAK2 V617F mutation identifies a subgroup of MDS patients with isolated deletion 5q and a proliferative bone marrow
41. Reduced-intensity conditioned allogeneic haematopoietic transplantation in an adult with Langerhans’ cell histiocytosis and thrombocytopenia with absent radii
42. Tumor supernatant from myeloid malignancies inhibits T-cell apoptosis and cell cycle entry independently
43. Ancestim associated with Filgrastim and/or chemotherapy can improve blood progenitor yields in patients who previously failed mobilisation
44. The effect of interleukin-7 on the alloreactivity of human T cells depends on the timing of its administration in relation to the allostimulus
45. Rituximab is effective in the management of refractory autoimmune cytopenias occurring after allogeneic stem cell transplantation
46. Differentially expressed genes in adult familial myelodysplastic syndromes
47. Dose-limiting dermatological toxicity secondary to imatinib mesylate (STI571) in chronic myeloid leukaemia
48. Reduced-intensity rituximab-BEAM-CAMPATH allogeneic haematopoietic stem cell transplantation for follicular lymphoma is feasible and induces durable molecular remissions
49. Response to Peggs et al.
50. Antigen gene transfer to cultured human dendritic cells using recombinant avipoxvirus vectors
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.